Cartesian Therapeutics, Inc. RNAC

About Cartesian Therapeutics, Inc. (RNAC): stock profile, AI score and financials

Cartesian Therapeutics, Inc. (RNAC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RNAC at 8.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,896 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.4) and revenue scale (0.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Cartesian Therapeutics, Inc. reports net income of $15.8M, free cash flow of $-21.4M. Top institutional holders of RNAC by reported 13-F value include Squarepoint Ops, BlackRock, 683 Capital Management, based on the most recent SEC filings. RNAC trades on the Nasdaq exchange and files with the SEC under CIK 1453687. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RNAC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cartesian Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1453687 →